Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
6.65
+0.08 (1.22%)
At close: Jun 27, 2025, 4:00 PM
6.33
-0.32 (-4.81%)
After-hours: Jun 27, 2025, 4:05 PM EDT
Quanterix Revenue
Quanterix had revenue of $30.33M in the quarter ending March 31, 2025, a decrease of -5.40%. This brings the company's revenue in the last twelve months to $135.69M, up 7.71% year-over-year. In the year 2024, Quanterix had annual revenue of $137.42M with 12.30% growth.
Revenue (ttm)
$135.69M
Revenue Growth
+7.71%
P/S Ratio
1.81
Revenue / Employee
$288,085
Employees
471
Market Cap
258.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 137.42M | 15.05M | 12.30% |
Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
QTRX News
- 5 days ago - Quanterix Expands Reach with IVD and Large Reference Labs - Business Wire
- 17 days ago - Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders - PRNewsWire
- 21 days ago - Quanterix to Present at Goldman Sachs Global Healthcare Conference - Business Wire
- 5 weeks ago - Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal - PRNewsWire
- 6 weeks ago - Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Quanterix Releases Financial Results for the First Quarter of 2025 - Business Wire
- 7 weeks ago - AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA - Business Wire
- 7 weeks ago - Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025 - Business Wire